About bipolar disorder therapeutics
Bipolar disorder is a psychological disorder characterized by intermittent mood swings. The individual suffering with this disorder experiences extreme poles of either mania or depression or both. The disorder severely affects the personal, social, and professional life of an individual. The symptoms usually include drastic changes in mood, either as a manic episode or a depressive episode. There is no complete cure for the disorder. Atypical antipsychotics, mood stabilizers, and antidepressants are being widely used in for treatment. It is considered as a lifelong disease and the discontinuation of the medication can lead to relapse of the condition.
Technavio's analysts forecast the global bipolar disorder therapeutics market to grow at a CAGR of 2.24% over the period 2014-2019.
Covered in this report
The report covers the present scenario and growth prospects of the global bipolar disorder therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of bipolar disorder.
Technavio's report, Global Bipolar Disorder Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global bipolar disorder therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Biopolar Disorder Therapeutics Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Biopolar Disorder Therapeutics Market: Allergan, AstraZeneca, BMS, Eli Lilly, GSK and Janssen Pharmaceuticals
Other Prominent Vendors in the market are: AbbVie, Abital Pharma, Astellas, Convergence Pharmaceuticals, D Pharm, Delpor, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Novartis, Noven Pharmaceuticals, Omeros Corporation, Otsuka, Pfizer, PNBDevCo, Reviva Pharmaceuticals, SK Biopharmaceuticals, and Sunovion Pharmaceutical.
Commenting on the report, an analyst from Technavio’s team said: “The rise in awareness about the disorder has led to increased understanding among the public. This has led to a rise in the number of individuals seeking medical attention for the treatment of the disorder. Also, strategic alliances formed between vendors help in increased penetration of the drugs in the market and increase market share.”
According to the report, an increase in the patient pool has been observed due to the increased identification of the disease because of awareness programs. Current treatment options do not provide a cure for the disorder, therefore, there is a significant unmet need in the market. Drugs that can cause remission of depression and mania in patients are therefore expected to drive the growth of the market.
Further, the report states that the lack of availability of diagnostic procedures for the identification of the disorder is a major challenge faced by the bipolar disorder therapeutics market.
Allergan, AstraZeneca, BMS, Eli Lilly, GSK, Janssen Pharmaceuticals, AbbVie, Abital Pharma, Astellas, Convergence Pharmaceuticals, D Pharm, Delpor, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Novartis, Noven Pharmaceuticals, Omeros Corporation, Otsuka, Pfizer, PNBDevCo, Reviva Pharmaceuticals, SK Biopharmaceuticals, Sunovion Pharmaceutical.